Program overview
Context
Indication: Neoadjuvant
Mechanism: Unknown
Modality: Unknown
Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology
Watchlist Signal
Pembrolizumab, Eftilagimod alfa
Pembrolizumab, Eftilagimod alfa is flagged as watchlist signal because public records show timeline staleness. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 1/5
Timeline: 2/5
Recruitment burden: 1/5
Results availability: 0/5
Program risk: 2/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT06128863
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT06128863 | Low Signal (ACTIVE_NOT_RECRUITING) | primary_completion_date_past_signal | long_recruitment_duration_signal | Low Signal | strict_eligibility_signal |